BioSpace News Archive

Tevard Biosciences today announced an agreement to exclusively license “mRNA Amplifier” technology will help form the basis of Tevard’s third platform for addressing diseases in which a mutation has caused a reduction in or loss of a vital protein.

Accuray Incorporated (NASDAQ: ARAY) announced today that long-term follow-up data from a study of men and women with trigeminal neuralgia (TN) showed 72 percent continued to experience pain relief 10 years after receiving image-guided robotic radiosurgery treatments delivered with the CyberKnife® System.

Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it is fortifying its oncology and hematology research acumen by adding Shaalan Beg, M.D., M.S.C.S. to its Global Management Team.

Recursion, the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced its participation in the following upcoming investor conferences:

Royal Philips announced the launch of Ultrasound Workspace[OLK1] at the American College of Cardiology’s Annual Scientific Session & Expo. Philips Ultrasound Workspace [1] is an industry leading vendor-neutral echocardiography image analysis and reporting solution that can be accessed remotely via a browser.

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biopharma company developing cellular therapies for aging-related illnesses, chronic disorders, and other specific life-threatening conditions, announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with mild Alzheimer’s disease (AD) in Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Association.

Portage Biotech Inc., a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, provided an update on its clinical development programs and announced its development goals for the remainder of 2022.

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2021 and provided a company update.

CHARGE syndrome, which affects approximately one in 10,000 newborns worldwide, is associated with neurological and behavioural conditions like intellectual disability, attention deficit disorder, convulsions, and autism.

VBL Therapeutics today announced that it will host a key opinion leader (KOL) luncheon and seminar on ovarian cancer on Monday, April 11, 2022 at 12pm Eastern Time at the St. Regis Hotel in New York, NY.